1.- Lane JM, Russell L, Khan SN. Osteoporosis. Clin Orthop Res
2000;372: 139-150.
2.- Miller PD. Management of osteoporosis. Adv Int Med 1.999; 44:
175-207.
3.- Kleerekoper M. Osteoporosis: Protecting bone mass with
fundamentals and drug therapy. Geriatrics 1.999; 54: 38-43.
4.- Physician´s Guide to prevention and treatment of osteoporosis.
National Osteoporosis Fundation. 1.998, 2000 Washington. Disponible en la web de NOF:
http:// www. nof.org/physguide/inside_form.htm
5.- Weinstein RS, Manolagas SC. Apoptosis and Osteoporosis. Am J Med
2000;108: 153-164.
6.- Ferrari S, Rizzoli R, Bonjuor JP. Genetic aspects of
osteoporosis. Curr Op Rheumatol 1.999;11: 294-300.
7.- Bilezikian JP. Osteoporosis in men. J Clin Endocrinol Metab
1.999;84: 3.431-3.434.
8.- Adachi JD, Olszynski WP, Hanley DA, et al. Management of
corticosteroid-induced osteoporosis. Semin Arthr Rheum 2000;29: 228-251.
9.- Souberbielle JC, Cormier C, Kindermans C. Bone markers in
clinical practice. Curr Op Rheumatol 1.999:11: 312-319.
10.- Harris ST, Watts NB, Jackson RD, etl al. Four-year study of
intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of
blinded therapy followed by one year of open therapy. Am J Med 1.993;95: 557-567.
11.- Liberman UA, Weiss SR, Broll J, et al. Effects of three years
treatment with oral alendronate on fracture incidence in women with postmenopausal
osteoporosis. N Engl Med 1.995; 333: 1.437-1.443.
12.- Pols HAP, Felsenberg D, Hanley DA, Stepn J, Muñoz-Torres M,
Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B. Multinational
placebo-controlled, randomized trial of the effects of alendronate on bone density and
fracture risk in postmenopausal women with low bone mass: results of de FOSIT study.
Osteoporos Int 1.999;9: 461-468.
13.- Black D, Bauer D, Thompson D, Hochberg M, for the FIT Reseach
Group. The early antifracture efficacy of alendronate in women with osteoporosis: results
from FIT. Osteoporos Int 2.000; 11(suppl 2): S173.
14.- Orwol E, Ettinger M, Weiss S, et al. Alendronate treatment of
osteoporosis in men. J Bone Miner Res 1.999;14 (Suppl 1): S184.
15.- Boivin G, Santora AC, Yates J, Meunier P. In post-menopausal
osteoporotic women, alendronate augments bone strength by increasing the degree of
mineralization of bone tissue. Osteoporos Int 2000, 11 (Suppl 2): S209.
16.- Harris ST, Watts NB, Genant HK, et al. Effects of residronate
treatment on vertebral ans nonvertebral fractures in women with posmenopausal
osteoporosis. A randomized controlled trial. Vertebral Efficacy with Residronate Therapy
(VERT) Study Group. JAMA 1.999;282: 1.344-1.352.
17.- Woodson G. Once weekly residronate therapy. Osteoporos Int
2000; 11 (Suppl 2): S204.
18.- Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley
JA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women.
Results from de MORE randomized trial. JAMA 1999;281: 2189-2197.
19.- Silverman S, Chesnut C, Adriano K et al: Salmon calcitonin
nasal spray reduces risk of vertebral fracture(s) in established osteoporosis and has
continuos efficacy with prolonged treatment: Accrued 5 years wordwide data of the PROOF
study. Bone 1998, 23 (Suppl.5): S174.
20.- Silverman S, Chesnut C, Adriano K et al: Salmon calcitonin
nasal spray reduces the rate of new vertebral fracture independently of known major
pre-treatment risk factors: Accrued 5 years analysis of the PROOF study. Bone 1998, 23
(Suppl. 5): S290.
21.- Reginster JY, Meurmans L, Zegels B, et al. The effect of sodium
monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with
moderate osteoporosis: a randomized, controlled trial. Ann Intern Med 1.998;129: 1-8.
22.- Finkeltein JS, Klibanski A, Arnold A, Toth Tl, Hornstein MD,
Neer R. Prevention of estrogen deficiency related bone loss with human PTH: a randomized
controllez trial. JAMA 1.998:280: 1.067-1.073.
23.- Jilka RL, Weinstein RS, Bilido T, Roberson P, Parfitt AM,
Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with PTH. J
Clin Invest 1.999;104: 439-446.
24.- Abe E, Yamamoto M, Tazuchi V, Lecka-Czernik B. Essential
requirement of BMP-2 for both osteoblast and osteoclast formation in murine bone marrow
cultures. J Bone Miner Res 2000;15: 663-673.
25.- NIH Consensus Development Conference Statement. Osteoporosis
Prevention, Diagnosis and Therapy. March 27-29, 2000 (vol 17, nº 11). Disponible en:
http://odp.od.nih.gov/consensus/con/111/111_intro.htm
26.- Wordl Congress on Osteoporosis 2000. June, Chicago, Illinois
(EEUU). Resumenes disponibles a través de Medscape en: http://internalmedicine.medscape.com/Medscape/CNO/2000.
